RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study

被引：0
|
作者：
Catherine S. Tripp
Carolyn Cuff
Andrew L. Campbell
Barbara A. Hendrickson
Jeff Voss
Terry Melim
Chengbin Wu
Andrew D. Cherniack
Kenneth Kim
机构：
[1] AbbVie,
[2] Global Pharmaceutical R&D,undefined
[3] AbbVie,undefined
[4] Global Pharmaceutical R&D,undefined
[5] WCCT Global LLC,undefined
[6] EpimAb Biotherapeutics Inc.,undefined
[7] Broad Institute of MIT and Harvard,undefined
来源：
Advances in Therapy | 2017年 / 34卷
关键词：
Asthma; IL-13; Respiratory;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1364 / 1381
页数：17
相关论文
共 50 条
  • [41] A phase 1, first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending intravenous dose study of VGL101, a novel TREM2 agonist, in healthy adult volunteers (HVS)
    Meier, Andreas
    Papapetropoulos, Spyros
    Marsh, Andrew
    Neelon, Kelly
    Thackaberry, Evan
    Stiles, David
    O'Mara, Ryan
    Rajagovindan, Raj
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [42] A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Evaluate the Efficacy and Safety of Clazakizumab, an Anti-IL-6 Monoclonal Antibody, in Adults with Active Psoriatic Arthritis.
    Mease, Philip
    Gottlieb, A. B.
    Berman, A.
    Drescher, E.
    Xing, J.
    Banerjee, S.
    Wong, R.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S423 - S423
  • [43] Results From a Multicenter, International, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Sirukumab, a Human Anti-IL-6 Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy.
    Hsu, Benjamin
    Sheng, Shihong
    Weinblatt, Michael E.
    Smolen, Josef
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S1035 - S1035
  • [44] Efficacy and Safety Results of Guselkumab, an Anti-IL23 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis over 24 Weeks: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
    Deodhar, Atul A.
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Barchuk, William
    Xu, Xie
    Hsia, Elizabeth C.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [45] EFFICACY AND SAFETY RESULTS OF GUSELKUMAB, AN ANTI-IL23 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 24 WEEKS: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Deodhar, A.
    Gottlieb, A.
    Boehncke, W. -H.
    Dong, B.
    Wang, Y.
    Barchuk, W.
    Xu, X. L.
    Hsia, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 142 - 143
  • [46] A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
    Papp, K.
    Pariser, D.
    Catlin, M.
    Wierz, G.
    Ball, G.
    Akinlade, B.
    Zeiher, B.
    Krueger, J. G.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (03) : 767 - 776
  • [47] A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel spiroindolone KAE609, to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers
    Joel Leong
    Ruobing Li
    Jay Prakash Jain
    Gilbert Lefèvre
    Baldur Magnusson
    Thierry Diagana
    Peter Pertel
    Malaria Journal, 13 (Suppl 1)
  • [48] RESULTS FROM A 2-PART, PROOF-OF-CONCEPT, DOSE-RANGING, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF SIRUKUMAB, A HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
    Hsu, B.
    Sheng, S.
    Smolen, J. S.
    Weinblatt, M. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 188 - 188
  • [49] A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Imidazolopiperazine KAF156 To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers
    Leong, F. Joel
    Zhao, Rong
    Zeng, Shuqi
    Magnusson, Baldur
    Diagana, Thierry T.
    Pertel, Peter
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (11) : 6437 - 6443
  • [50] A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects
    Fei, Yue
    Li, Na
    Qian, Weilin
    Fan, Yang
    Shen, Yu
    Wang, Quanren
    Mclendon, Kristi
    Shen, Kai
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345